Publications

Authors: Prof. Dr. Mike K.S. Chan, Prof. Dr. Michelle B.F. Wong, Dr. Shing Yi Pan, Dr. Volodymyr Chernykh, Dr. Nataliia Shyshkina, Dr. Margaryta Yemeliyanova, Dr. Dmytro Klokol, Dr. Olha Nishkumai, Dr. Glen Alvin, Oleg Kobzev, Svitlana Dubynska and Jonathan Lakey
Publisher: SSP Modern Pharmacy and Medicine; 5(3), 2025
Publisher's URL: https://doi.org/10.53933/61x4gw93

MORE PUBLICATIONS:
https://european-wellness.eu/publications/

Authors: Dr. Dmytro Klokol, Prof. Dr. Mike K.S. Chan, Prof. Dr. Michelle B.F. Wong, Dr. Volodymyr Chernykh, Dr. Margaryta Iemelianova and Dr. Glen Alvin
Publisher: Journal of Stem Cell Research; 6(2), 2025
Publisher's URL: https://doi.org/10.52793/JSCR.2025.6(2)-74

MORE PUBLICATIONS:
https://european-wellness.eu/publications/

A groundbreaking review article in Molecular Biology Reports maps out why the α-Klotho protein is fast becoming a keystone molecule for both healthy longevity and oncology! Co-authored by European Wellness founder Prof. Dato’ Sri Dr. Mike Chan along with an international team of researchers, the study reveals how Klotho might hold the key to aging and conditions such as cancer.

What makes Klotho so special?

• It acts like a control switch for major cell pathways – including Wnt, IGF-1, PI3K/AKT, and TGF-β – helping to prevent runaway cell growth and tissue damage.
• It has strong antioxidant and anti-inflammatory powers, which protect our DNA and slow down age-related wear and tear.
• In many cancers (like breast, liver, and T-cell cancers), Klotho levels are observed to drop. Restoring it may potentially hold the key to addressing cancer growth and spread.
• Researchers are developing cutting-edge ways to bring Klotho back – including gene therapy, peptides, and smart nanoparticles.

MORE PUBLICATIONS:
https://european-wellness.eu/publications/

💡 What’s Inside?
This cutting-edge review explores two next-generation peptide platforms: Nano-Organo Peptides (NOPs) and Mitochondria-Targeted Peptides (MTPs) as precision therapies for Acute Kidney Injury (AKI) and Chronic Kidney Disease (CKD).

📌 Key Highlights:
✔️ Nano-Organo Peptides (NOPs): Deliver peptides to subcellular compartments (e.g., mitochondria, lysosomes, ER) for targeted renal repair
✔️ Mitochondria-Targeted Peptides (MTPs): Protect kidney mitochondria by stabilizing cardiolipin, reducing oxidative stress, and restoring bioenergetics
✔️ Promising results in fibrosis attenuation, immune modulation, glomerular protection, and tubular cell survival
✔️ Therapeutic examples like SS-31 (elamipretide) show effectiveness in ischemia-reperfusion injury, diabetic nephropathy, and age-related renal decline
✔️ Highlights early clinical studies, renal-targeted delivery strategies, and emerging precision nephrology applications

This review outlines the scientific rationale, delivery systems, mechanistic targets, and clinical potential of peptide-based therapeutics in nephrology, opening new pathways for overcoming the limitations of conventional kidney treatments.

MORE PUBLICATIONS:
https://european-wellness.eu/publications/

💡 About the Publication:

This powerful review explores how mesenchymal stem cells (MSCs) and neural stem/progenitor cells (NSPCs) offer transformative potential in the treatment of complex neurodegenerative and neuroinflammatory diseases such as Alzheimer’s, Parkinson’s, ALS, MS, stroke, TBI, and SCI.

These two stem cell types are uniquely positioned to:

✔️ Address key pathologies like neuronal loss, inflammation, and blood-brain barrier (BBB) dysfunction
✔️ Promote cell replacement, neuroprotection, synaptic plasticity, and remyelination
✔️ Deliver therapeutic effects through direct regeneration and powerful paracrine signaling
✔️ Reduce oxidative stress and neuroinflammation, while enhancing recovery through trophic and immunomodulatory actions

With insights from clinical and preclinical models, the article also compares the unique advantages and limitations of MSCs and NSPCs and provides a roadmap for optimizing their clinical translation

MORE PUBLICATIONS:
https://european-wellness.eu/publications/

Unlock the future of healing with Compendium of Diseases and Disorders: Clinical Applications of Stem Cells with Precision in Regenerative Medicine. Authored by pioneering scientist Prof. Dr. Mike Chan, this groundbreaking volume bridges cutting-edge research and real-world clinical application. It explores how targeted progenitor and precursor stem cells can transform the treatment of a wide range of diseases—from neurodegenerative conditions and cardiovascular disorders to aging-related syndromes and immune deficiencies. Designed for healthcare professionals, researchers, and innovators, this compendium offers a visionary yet practical guide to the evolving frontiers of regenerative medicine, emphasizing precision, ethical responsibility, and hope for conditions once deemed untreatable.

Prof. Dr. Mike K.S. Chan is an author, educator, and pioneer in Cellular, Organo, and Cell Membrane Therapies in Europe and Asia since the early 1980s. He founded one of the world’s largest research groups in Bio-Molecular Medicine, headquartered in Switzerland and Germany, with a global presence in nearly eighty countries. He has delivered more than 1,000 lectures, seminars, and symposiums worldwide in the fields of anti-aging, cell regeneration, bio-regenerative medicine, and stem cell therapies.
He is the author or co-author of over 60 scientific and medical books covering stem cells, aging, neurodegenerative and neurodevelopmental disorders, metabolic diseases, and biological as well as regenerative medicine. Prof. Dr. Chan serves on the board and chairs the Scientific Committee for Regenerative Medicine at ESAAM. He is also an Associate Professor at AASCP, USA; an Adjunct Professor and Fellow of Lincoln University College, USA (Kuala Lumpur campus); Chairman of the Medical Association for Regenerative Medicine in Japan (MMJ – Multi-Dimensional Holistic Medical Team Japan); and a Senator of BWA, Germany (Federal Association for Economic Development and Foreign Trade), representing China, Indonesia, and Malaysia.
He has played a pivotal role in advancing medical and wellness tourism, as well as educational tourism, in Switzerland, Germany, and Malaysia collaborating with physicians from the USA, Portugal, Poland, Belgium, China, Spain, the UK, Indonesia, Taiwan, Australia, New Zealand, Thailand, Singapore, Vietnam, the Philippines, and the Middle East.

Prof. Dr. Michelle B.F. Wong is a distinguished scientist, researcher, and educator, actively engaged in stem cell research and development (R&D), with a particular focus on fetal precursor stem cell therapy. For over three decades, she has served as Co-Founder, Senior Technical Advisor, and Researcher at FCTI Inc., a company specializing in stem cell research and bio-regenerative medicine.Her solid academic foundation in nutrition and naturopathy has facilitated a seamless transition into R&D within the field of stem cell bioregenerative medicine.
Dr. Wong is also a highly respected speaker, regularly delivering presentations at educational programs and international conferences on topics such as stem cells, cell therapy, and biological medicine—benefiting physicians and healthcare practitioners worldwide.

💡 About the Publication:

This comprehensive review explores the cutting-edge advancements in stroke and brain injury management, focusing on the revolutionary integration of cellular, molecular, and regenerative therapies.

📌 Key Highlights:

✔️ Explores the complex biological mechanisms of neurodegeneration and repair
✔️ Showcases the role of stem cells, peptides, and mitochondrial therapies in promoting neuroregeneration
✔️ Highlights the latest developments in personalized medicine, neurorehabilitation, and neuroprotective strategies
✔️ Bridges neuroscience, regenerative medicine, and functional recovery—offering renewed hope for patients with neurological injuries

This publication represents the next generation of neurorepair science, merging evidence-based research with futuristic approaches to restore brain function and enhance patient quality of life.

MORE PUBLICATIONS:
https://european-wellness.eu/publications/

Authors: Prof. Dr. Mike K.S. Chan, Siti Azmah Jambo, Mohd. Iskandar Jumat, Florisa Landa, Nur Shafawati Saili, Dianah Florentius, Nuryasmin Ezzaty, Raz Haziqah Hani Razali, Brenda Song Pei Chui, Aziera Farhanah Adihidayah Suardi, Sze Huey Sang, Dr. Dmytro Klokol, Dr. Olha Nishkumai, Dr. Margarita Iemeliyanova, Dr. Yuriy Nalapko, Thomas Skutella, Jonathan R.T. Lakey and Prof. Dr. Michelle B.F. Wong
Publisher: Journal of Stem Cell Research; 6(1), 2025
Publisher's URL: https://doi.org/10.52793/JSCR.2025.6(1)-71

MORE PUBLICATIONS:
https://european-wellness.eu/publications/

With over 830 million people affected globally, metabolic syndrome and type 2 diabetes are among the fastest-growing chronic conditions of our time. This study introduces a groundbreaking, non-pharmacological prevention strategy using low-intensity neuromuscular and musculoskeletal activation exercises—tailored especially for individuals with mobility limitations.

📌 Key Findings:

✔️ Up to 20.4% reduction in post-meal blood glucose levels

✔️ Significant decrease in systolic and diastolic blood pressure

✔️ Effective activation of GLUT4 and AMPK pathways—even without insulin

✔️ Positive outcomes achieved in just 12 minutes of seated exercise

✔️ Supports cardiovascular health, metabolic balance, and anti-aging benefits

These results highlight how structured, accessible exercise routines can be a vital part of bioregenerative medicine, improving glycemic control and promoting healthy aging—especially in populations with limited access to conventional therapies.

MORE PUBLICATIONS:
https://european-wellness.eu/publications/

In a groundbreaking study, researchers are now exploring the potential of using a patient’s own bone marrow-derived stem cells to provide stem cell therapy for managing diabetes – essentially harnessing the body’s own power! 💪

Here are some key insights…

✅ A Safer Approach: Could using a patient’s own bone marrow stem cells (autologous BMMNCs) offer a potentially safer route for diabetes therapy by minimizing risks seen with donor cells?

✅Potential for Better Control: Clinical studies suggest autologous BMMNC infusion holds promise for improving blood sugar levels (HbA1c) and possibly reducing insulin needs in Type 1 & Type 2 Diabetes.

✅ Hope for Patients with Complications: This therapy shows potential for addressing difficult diabetes-related issues e.g. conditions like kidney problems (nephropathy) or non-healing foot ulcers.

MORE PUBLICATIONS:
https://european-wellness.eu/publications/